Literature DB >> 11749116

Coadministration of antigen and particles optimally stimulates the immune response in an intranasal administration model in mice.

M van Zijverden1, C de Haar, A van Beelen, H van Loveren, A Penninks, R Pieters.   

Abstract

Some particulate matter is known to affect human health, yet the mechanism(s) by which it acts is largely unknown. One of the factors that may play a role in the immune- stimulating activity of particles is binding of allergen to particles. This may turn the particles into allergen carriers, resulting in antigen deposition within the altered inflammatory microenvironment created by the particles. We compared the efficacy of simultaneous versus separate administration of antigen and particles during sensitization in an intranasal exposure model in BALB/c mice. Sensitization consisted of three separate doses (10 microg) of TNP-OVA at Days 1, 2, and 3. Two hundred micrograms of carbon black particles (CBP) were administered either 1 day before sensitization (Day 0), 1 day after sensitization (Day 4), or during sensitization. The latter was performed either at Day 1 (200 microg) or at Days 1, 2, and 3 (67 microg/day). At Day 10 a challenge with 10 microg of TNP-OVA was performed, and at Day 15 the immune response was assessed. The total number of cells as well as antibody-forming cells (AFC) in lymph nodes draining the lung (peribronchial lymph nodes [PBLN]) were determined, and immunoglobulin levels in blood were assessed. Cell numbers of PBLN increased significantly in all particle-treated groups compared to controls. The number of TNP-specific IgG1-forming cells in the groups receiving particles during sensitization was significantly higher than control level. Only groups receiving particles during or before sensitization displayed significantly higher IgG1 levels than controls, in contrast to the group receiving particles after sensitization. Only in animals receiving three doses of 67 microg during sensitization did TNP-specific IgE increase significantly compared to controls. IgG2a did not show significant differences compared to controls, indicating that the response is predominantly Th2 mediated. These data indicate that coadministration of particles at all time points of antigen dosing is the most effective way to stimulate an immune response in our model compared to separate particle and antigen dosing. Also, administration shortly before antigen administration was effective in stimulating an immune response, suggesting that time-dependent processes are involved in immune-stimulating activity of particles, supporting the important role of the altered inflammatory microenvironment created by the particles. c)2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11749116     DOI: 10.1006/taap.2001.9306

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  4 in total

1.  Investigating the potential for interaction between the components of PM(10).

Authors:  Vicki Stone; Martin R Wilson; Janet Lightbody; Kenneth Donaldson
Journal:  Environ Health Prev Med       Date:  2003-01       Impact factor: 3.674

2.  The allergy adjuvant effect of particles - genetic factors influence antibody and cytokine responses.

Authors:  Unni Cecilie Nygaard; Audun Aase; Martinus Løvik
Journal:  BMC Immunol       Date:  2005-06-21       Impact factor: 3.615

3.  Effect of Carbon Black Nanoparticle on Neonatal Lymphoid Tissues Depending on the Gestational Period of Exposure in Mice.

Authors:  Atsuto Onoda; Saki Okamoto; Ryuhei Shimizu; Yasser S El-Sayed; Shiho Watanabe; Shuhei Ogawa; Ryo Abe; Masao Kamimura; Kohei Soga; Ken Tachibana; Ken Takeda; Masakazu Umezawa
Journal:  Front Toxicol       Date:  2021-08-11

4.  Autocrine ligands of the epithelial growth factor receptor mediate inflammatory responses to diesel exhaust particles.

Authors:  Sam Parnia; Lynnsey M Hamilton; Sarah M Puddicombe; Stephen T Holgate; Anthony J Frew; Donna E Davies
Journal:  Respir Res       Date:  2014-02-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.